Novartis AG’s NOVN.S medication has been authorised by the US Food and Drug Administration for the treatment of patients with a kind of advanced prostate cancer that has spread to other regions of the body, the pharmaceutical announced on Wednesday.
Novartis’ Pluvicto is a targeted radioligand therapy for adult patients who have already received anticancer treatment.
The treatment was purchased as part of the company’s $2.1 billion purchase of cancer pharmaceutical Endocyte in 2018.
According to Novartis, Pluvicto is a precision medicine that combines a targeted chemical, or ligand, with a cancer-killing radioactive particle.
Pluvicto has been filed for marketing permission to the European Medicines Agency and other health authorities, according to the business.
According to Novartis, two late-stage trials investigating Pluvicto in early lines of therapy for metastatic prostate cancer are now underway.
